Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) engages in the research, development, manufacture, and sale of pharmaceutical preparations and active pharmaceutical ingredients (APIs), with a focus on cardiovascular, cerebrovascular, and anti-tumor drugs. The company offers core products including cosunternib capsules for tumor treatment; injections such as cosunternib and irinotecan hydrochloride; and oral preparations like oseltamivir phosphate capsules and sustained-release tablets for antiviral applications; alongside APIs including high-end chemical drugs and contrast agents. It operates primarily in the pharmaceutical industry, targeting domestic hospitals, pharmacies, and distributors in China, with headquarters in Fuzhou, Fujian province, where it was founded in 2002.
In recent developments, the company expanded its production capabilities through the completion of a new API project in 2024, enhancing capacity for key intermediates and boosting overall manufacturing efficiency. Additionally, Fujian Cosunter formed strategic partnerships with leading research institutions for new drug development pipelines, including Phase III clinical trials for innovative cardiovascular therapies announced in late 2024. No major acquisitions, funding rounds, or name changes were reported in the last 1-2 years, though the firm continues to invest in R&D for biologics and expanded its geographic footprint within China via new distribution agreements.